DQ 113

Drug Profile

DQ 113

Alternative Names: D 611113; DQ-113

Latest Information Update: 17 Feb 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Pharmaceutical
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 17 Feb 2006 Discontinued - Preclinical for Gram-positive infections in Japan (unspecified route)
  • 03 Jan 2002 A preclinical study has been added to the pharmacokinetics section
  • 03 Jan 2002 Two in vitro studies have been added to the Bacterial Infections antimicrobial activity section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top